http://www.medicalnewstoday.com/medicalnews.php?newsid=66667 - Well, at least Europe is paying attention and has the courage to just say no. The European Medicines Agency (EMEA) has recommended restrictions on the use of Ketek (telithromycin) in three of its four approved indications. For the treatment of bronchitis, sinusitis, and tonsillitis/pharyngitis, Ketek should only be used for infections caused by bacterial strains that are suspected or proven to be resistant to or cannot be treated with macrolide or beta-lactam antibiotics. No such restrictions are recommended for the remaining indication, the treatment of community-acquired pneumonia.
The Agency's Committee for Medicinal Products for Human Use also recommended the contraindication of the use of Ketek in patients with myasthenia gravis and strengthened warnings on transient loss of consciousness and effects on vision.
